Sherman Morris, Shafran Stephen, Burak Kelly, Doucette Karen, Wong Winnie, Girgrah Nigel, Yoshida Eric, Renner Eberhard, Wong Philip, Deschênes Marc
Department of Medicine, University of Toronto, Toronto General Hospital, Toronto, Canada.
Can J Gastroenterol. 2007 Jun;21 Suppl C(Suppl C):5C-24C.
The present document presents the proceedings of the consensus development conference on the management of viral hepatitis held in January 2007 under the auspices of the Canadian Association for the Study of the Liver and the Association of Medical Microbiology and Infectious Disease Canada. Several new agents have become available since the last such document was published in 2004, and new information has become available to help assess risk of adverse outcomes and who should be treated. In addition, the participants at the meeting identified a number of structural barriers that exist uniquely in Canada and that prevent physicians from properly managing their patients. The conference discussed the selection of patients for treatment and the drugs that can be used to treat these patients, as well as the treatment of hepatitis B in special populations. The present document should be read in conjunction with the companion document on the management of chronic hepatitis C.
本文件介绍了2007年1月在加拿大肝脏研究协会以及加拿大医学微生物学与传染病协会的支持下召开的病毒性肝炎管理共识发展会议的会议记录。自上一份此类文件于2004年发布以来,已有几种新药物可供使用,并且有了新的信息来帮助评估不良后果风险以及哪些人应该接受治疗。此外,会议参与者确定了一些加拿大特有的结构性障碍,这些障碍阻碍医生对患者进行妥善管理。会议讨论了治疗患者的选择、可用于治疗这些患者的药物,以及特殊人群中的乙型肝炎治疗。本文件应与关于慢性丙型肝炎管理的配套文件一并阅读。